Federal Grant Award Summary

The University of New Mexico Health Sciences Center received a $419,375 Project Grant from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective July 1, 2026 through June 30, 2028. The award supports research investigating the mechanisms of vascular dysfunction in Down syndrome, with specific focus on understanding how endothelial glycocalyx depletion contributes to cardiovascular disease risk. Using the TCMAC21 mouse model of Down syndrome, researchers will examine the relationship between oxidative stress, inflammation, endothelial cell autophagy, and cellular senescence in the development of endothelial dysfunction—conditions known to accelerate cardiovascular aging in individuals with Down syndrome.

The project delivers original research findings in a previously understudied area, as no prior studies have investigated the glycocalyx in Down syndrome human or animal models. By characterizing the molecular and cellular mechanisms underlying vascular dysfunction in Down syndrome, the award generates foundational knowledge that may inform future therapeutic interventions to reduce cardiovascular disease mortality in this population. The research is conducted at the University of New Mexico's Albuquerque campus and leverages the institution's biomedical research infrastructure and expertise in translational investigations.